ARS Pharmaceuticals, Inc. (SPRY) stock

SPRYNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/30

$3.89+0.08 (+2.10%)

Close on Nov 13, 2026Market cap $386.85MP/E –Yield –

ARS Pharmaceuticals total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

ARS Pharmaceuticals's total debt was $0 at Dec 31, 2022. For fiscal 2022 it was $0, down 100.0% from the year before.

Period	Period end	Value	Change
FY2022	Dec 31, 2022	$0	-100.0%
FY2021	Dec 31, 2021	$4.93M	–

Change is against the same quarter a year earlier.

Period	Period end	Value	Change
Q4 FY2022	Dec 31, 2022	$0	–
Q4 FY2021	Dec 31, 2021	$4.93M	–

Parsed from the XBRL in ARS Pharmaceuticals's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is SPRY.

Revenue growth-14.5% · median 110.0%

Operating margin-161.5% · median -56.2%

Net margin-163.6% · median -153.3%

Advertisement
300 × 250

See a number that looks wrong?